Global Health Investment Corporation

Global Health Investment Fund

Our namesake $108 million social impact investment fund, the Global Health Investment Fund (GHIF), has invested in companies developing interventions such as diagnostics, devices, vaccines and therapeutics that target diseases that  disproportionately burden people living in low- and middle-income countries. GHIF’s portfolio companies have registered 13 products that have reached over 100 million people, improving global health and saving lives.

GHIF's financial performance has demonstrated that it is possible to generate meaningful financial returns by investing public, philanthropic, and private capital in global health product development.

The Global Health Investment Fund focuses on a wide range of infectious diseases and maternal/infant health conditions, including HIV/AIDS, malaria, tuberculosis, cholera, chikungunya, river blindness, and pre-eclampsia. Increasing access to existing products and interventions is also part of GHIF's mission. Most recently, several of the GHIF companies launched successful COVID-19 programs.

The innovative investment model pioneered by GHIC through its Global Health Investment Fund has also stimulated the launch of additional investment funds seeking to build upon this model and further magnify its impact.

GHIF Portfolio Investments

Access Bio . Opens in new tab.

Intervention: Diagnostic

Targets: Malaria, G6PDd, HIV, dengue, HPV, Zika

Impact Objectives: Reduced cost of high-quality malaria RDTs; new, low-cost diagnostics for other diseases

Alydia Health . Opens in new tab.

Intervention: Device

Targets: Postpartum hemorrhage

Impact Objectives: Develop new gold-standard intervention for PPH

Atomo Diagnostics . Opens in new tab.

Intervention: Diagnostic

Targets: HIV, Ebola, HCV, malaria

Impact Objectives: Improved professional testing and self-testing

BD . Opens in new tab.

Intervention: Diagnostic

Targets: Preeclampsia (PE), gestational diabetes mellitus (GDM)

Impact Objectives: Early, affordable, point-of-care PE/GDM testing; ↓ maternal/infant mortality/morbidity

EUBiologics . Opens in new tab.

Intervention: Vaccine

Targets: Cholera

Impact Objectives: Increase global supply of affordable vaccine doses; deliver improved presentation at $1/dose

Genedrive . Opens in new tab.

Intervention: Diagnostic

Targets: Tuberculosis (TB), HCV

Impact Objectives: Diagnosis of TB and HCV on a near-point-of-care molecular diagnostic platform, enabling more effective treatment

IanTech . Opens in new tab.

Intervention: Surgical device

Targets: Cataract-induced blindness and visual impairment

Impact Objectives: Expand access to vision-restoring cataract surgery in resource-limited settings

Moxidectin . Opens in new tab.

Intervention: Treatment

Targets: Onchocerciasis (river blindness)

Impact Objectives: Accelerate the eradication of onchocerciasis; improve treatment outcomes

PATH . Opens in new tab.

Intervention: Treatment

Targets: Hookworm, Roundworm, Whipworm

Impact Objectives: Cure hundreds of millions of school-aged children from parasitic worm infections; expand the arsenal of anthelmintics

Serum Institute of India . Opens in new tab.

Intervention: Vaccines and therapeutics

Targets: Anti-venom for snakebites, vaccines for tuberculosis and pertussis

Impact Objectives: High-quality anti-venoms, increased access to Tdap vaccines in pregnancy, more effective protection against tuberculosis

Themis Bioscience . Opens in new tab.

Intervention: Vaccine platform

Targets: Chikungunya, Zika

Impact Objectives: Protect at-risk communities from public health challenges such as mosquito-transmitted viruses

Univercells . Opens in new tab.

Intervention: Biologics manufacturing technology platform

Targets: Polio, Measles, Rubella

Impact Objectives: Dramatic reductions in the cost of essential biologics; distributed manufacturing

"The private sector has all the tools to do the job. What is required is an innovative spirit, and a willingness to be as bold in the social arena as corporations are in the marketplace." – Jamie Dimon, Chairman and CEO, JP Morgan Chase & Co.